Therapeutic potential of investigational CHK-1 inhibitors for the treatment of solid tumors

Hani M. Babiker, Ali McBride, Laurence S. Cooke, Daruka Mahadevan

Producción científica: Review articlerevisión exhaustiva

9 Citas (Scopus)

Resumen

Introduction: For several decades’ cancer treatment targeting DNA repair pathways incorporated both chemo- and radiotherapy only. However, over the last decade improved knowledge of DNA repair processes has paved the way for the development of novel targeted drugs abrogating DNA repair signaling. Checkpoint kinase inhibitors are exciting molecules and hold promise in the treatment of both solid and hematologic malignancies. Herein, we discuss preclinical and clinical studies with this class of molecules. Areas covered: In this review, we discuss the role of check point kinase 1 (CHK-1) in DNA repair and provide a comprehensive summary of pre-clinical and early phase clinical trials with CHK-1 inhibitors. We also provide molecular structural basis of CHK-1inhibitors binding to CHK-1. Expert opinion: Available data from both pre-clinical and early clinical studies illustrates potential efficacy of this class of molecules when combined with antimetabolites in treating both solid and hematologic malignancies. In addition, there might be an additive role in combining this class of molecules to PARP inhibitors, platinum chemotherapy, or radiation therapy in p53 or BRCA mutated tumors. The safety of the aforementioned combination needs to be closely evaluated in the ongoing clinical trials.

Idioma originalEnglish (US)
Páginas (desde-hasta)1063-1072
Número de páginas10
PublicaciónExpert Opinion on Investigational Drugs
Volumen26
N.º9
DOI
EstadoPublished - sept 2 2017
Publicado de forma externa

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology

Huella

Profundice en los temas de investigación de 'Therapeutic potential of investigational CHK-1 inhibitors for the treatment of solid tumors'. En conjunto forman una huella única.

Citar esto